Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063438 | 0.84 | SCN9A (0.48) | SCN9ADRD2DRD3DRD1DRD4 | |
| SCHEMBL20063492 | 0.81 | SCN9A (0.45) | SCN9A | |
| SCHEMBL20063857 | 0.80 | DRD2 (0.46) | SCN9ADRD2DRD3DRD1DRD4 | |
| SCHEMBL20063875 | 0.80 | DRD2 (0.46) | SCN9ADRD2DRD3DRD1DRD4 | |
| SCHEMBL23638938 | 0.78 | SCN9A (0.49) | SCN9A | |
| SCHEMBL20063874 | 0.77 | SCN9A (0.45) | SCN9ADRD2DRD3DRD1DRD4 | |
| SCHEMBL20063861 | 0.77 | SCN9A (0.45) | SCN9ADRD2DRD3DRD1DRD4 | |
| SCHEMBL23638940 | 0.76 | SCN9A (0.51) | SCN9A | |
| SCHEMBL20095930 | 0.75 | DRD2 (0.55) | SCN9ADRD2DRD3DRD1DRD4 | |
| SCHEMBL20095932 | 0.75 | DRD2 (0.55) | SCN9ADRD2DRD3DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SCN9A 1478/4885DRD2 1844/4885DRD3 1565/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885DRD2 1936/4885DRD3 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.